MedPath

Cardiol's CRD-38 Shows Promise in Heart Failure Treatment with Novel Cannabidiol Approach

• New data published in JACC demonstrates CRD-38's ability to improve cardiac function and reduce inflammation through its unique cannabidiol-based mechanism of action.

• Preclinical studies reveal CRD-38's subcutaneous administration resulted in reduced cardiac fibrosis, improved ejection fraction, and enhanced cardiac output in heart failure mouse models.

• The development addresses a growing unmet need in heart failure treatment, particularly significant given the increasing prevalence of the condition due to aging populations and rising cardiovascular risk factors.

Cardiol Therapeutics has unveiled promising new data in the Journal of the American College of Cardiology (JACC) demonstrating the therapeutic potential of their novel heart failure treatment, CRD-38. The cannabidiol-based therapy has shown significant improvements in cardiac function while reducing cardiac hypertrophy, remodeling, inflammation, and cell death.

Novel Mechanism of Action

CRD-38 represents an innovative approach to heart failure treatment through its dual mechanism of action. The drug functions as an agonist to cannabinoid receptors CB1 and CB2, with its cannabidiol component providing anti-inflammatory effects. Additionally, the organic nitrates in the compound directly relax vascular smooth muscles, leading to coronary vessel dilation and improved myocardial oxygen supply.

Compelling Preclinical Results

In preclinical studies using a mouse model of heart failure, researchers observed several positive outcomes following subcutaneous administration of CRD-38:
  • Reduced cardiac fibrosis
  • Decreased cardiac hypertrophy
  • Improved ejection fraction
  • Enhanced cardiac output

Addressing an Expanding Medical Need

The development of CRD-38 comes at a crucial time as heart failure prevalence continues to rise globally. This increase is attributed to:
  • An aging global population
  • Extended survival of cardiac patients due to modern therapeutic innovations
  • Growing prevalence of risk factors including hypertension, obesity, and diabetes

Treatment Administration Advantage

Key opinion leaders have noted that the subcutaneous delivery method of CRD-38 presents a significant advantage in the treatment landscape. Physicians have expressed preference for subcutaneous therapies over oral medications, as many heart failure patients already manage complex pill regimens.

Clinical Development Pipeline

Cardiol Therapeutics, headquartered in Oakville, Ontario, continues to expand its cardiovascular therapeutic portfolio. Beyond CRD-38, the company is advancing CardiolRx, another cannabidiol-based treatment currently in Phase II trials for multiple indications.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Highlighted Clinical Trials

CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation

NCT06708299RecruitingPhase 3
Cardiol Therapeutics Inc.
Posted 4/7/2025

Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)

NCT05494788Active, Not RecruitingPhase 2
Cardiol Therapeutics Inc.
Posted 11/30/2022

Related Topics

FDA Expands Jardiance Approval for All Heart Failure Patients, Regardless of Ejection Fraction

The FDA has approved Jardiance (empagliflozin) for treating a broader range of heart failure patients, making it the first drug approved for all heart failure patients regardless of ejection fraction status. The approval was based on the EMPEROR-Preserved phase III trial, which demonstrated a 21% relative risk reduction in cardiovascular death or hospitalization for heart failure.

Myocardial Infarction Therapeutics Pipeline Shows Promise with Over 45 Companies Involved

The myocardial infarction therapeutics pipeline is robust, featuring over 45 companies developing more than 50 potential drugs.
Key companies like Boehringer Ingelheim and Idorsia Pharmaceuticals are advancing novel therapies to improve outcomes post-myocardial infarction.

Cardiol Therapeutics Advances CardiolRx™ for Recurrent Pericarditis to Phase 3 Trial

Cardiol Therapeutics is advancing its lead drug, CardiolRx™, to a Phase 3 clinical trial (MAVERIC) for patients with recurrent pericarditis at high risk of recurrence.
CardiolRx™ is uniquely positioned to address critical gaps in current treatment options for recurrent pericarditis, potentially offering a safer, more cost-effective, and disease-modifying approach.

Cardiol Therapeutics Advances CardiolRx into Phase III Trial for Recurrent Pericarditis Following Positive Phase II Results

Cardiol Therapeutics is advancing its drug, CardiolRx, into a Phase III clinical trial (MAVERIC-3) for recurrent pericarditis after promising Phase II results.
The Phase II MAvERIC-Pilot study demonstrated sustained reductions in pericarditis pain and inflammation over 26 weeks with CardiolRx treatment.

Cardiol Therapeutics' CardiolRx Shows Promise in Phase II Trial for Recurrent Pericarditis

Cardiol Therapeutics' CardiolRx demonstrated significant improvements in pain and inflammation in patients with recurrent pericarditis during a Phase II open-label study.
The trial showed a substantial reduction in pericarditis episodes per year, from 5.8 to 0.9, with 71% of participants maintaining freedom from recurrence during the extension period.

Omecamtiv Mecarbil Shows Potential in High-Risk Heart Failure Patients: GALACTIC-HF Data

Post-hoc analysis of GALACTIC-HF indicates omecamtiv mecarbil's efficacy is consistent across age groups, including older patients with severe heart failure.
The study showed omecamtiv mecarbil reduces the risk of ventricular arrhythmias in patients with severely reduced left ventricular ejection fraction (LVEF).

Cardiol Therapeutics Added to PRISM Emerging Biotech Index

Cardiol Therapeutics has been included in the PRISM Emerging Biotech Index, recognizing its innovative approach to treating heart disease.
CardiolRx™, the company's lead drug candidate, has received FDA Orphan Drug Designation for pericarditis and is in Phase II/III trials.

HeartFlow's AI-Powered FFRCT Analysis Demonstrates Long-Term Benefits in CAD Evaluation

HeartFlow's FFRCT Analysis, when used with CCTA, significantly enhances the identification of lesions likely to benefit from revascularization in high-risk NSTE-ACS patients.
Data from ADVANCE-DK show HeartFlow technologies identify long-term residual risks of CAD, offering insights beyond immediate risks.

Cancer Drug Conatumumab Shows Promise in Treating Peripheral Artery Disease

Preclinical studies demonstrate that Conatumumab, previously tested as a cancer drug, effectively treats Peripheral Artery Disease (PAD).
The drug was tested in preclinical models of PAD and in vitro using cells and arteries from PAD patients who underwent amputation.

Device-Based Therapies Reshape Chronic Heart Failure Treatment Landscape

Device-based therapies are increasingly integral in managing chronic heart failure, offering solutions for structural and neurohormonal abnormalities.
The FDA's Breakthrough Device Program expedites access to innovative heart failure devices, fostering development and evaluation of these therapies.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy